|
1
|
Sierra-Sepúlveda A, Esquinca-González A,
Benavides-Suárez SA, Sordo-Lima DE, Caballero-Islas AE,
Cabral-Castañeda AR and Rodríguez-Reyna TS: Systemic sclerosis
pathogenesis and emerging therapies, beyond the fibroblast. Biomed
Res Int. 2019(4569826)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Barsotti S, Orlandi M, Codullo V, Di
Battista M, Lepri G, Della Rossa A and Guiducci S: One year in
review 2019: Systemic sclerosis. Clin Exp Rheumatol. 37 (Suppl
119):S3–S14. 2019.PubMed/NCBI
|
|
3
|
Juche A, Siegert E, Mueller-Ladner U,
Riemekesten G, Günther C, Kötter I, Henes J, Blank N, Voll RE,
Ehrchen J, et al: Reality of inpatient vasoactive treatment with
prostacyclin derivatives in patients with acral circulation
disorders due to systemic sclerosis in Germany. Z Rheumatol.
79:1057–1066. 2020.PubMed/NCBI View Article : Google Scholar : (In German).
|
|
4
|
Kowal-Bielecka O, Landewé R, Avouac J,
Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D,
Fligelstone K, et al: EULAR recommendations for the treatment of
systemic sclerosis: A report from the EULAR scleroderma trials and
research group (EUSTAR). Ann Rheum Dis. 68:620–628. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bobeica C, Niculet E, Halip AI,
Gheuca-Solovastru L, Draganescu ML, Popescu IA, Onisor C,
Chirobocea S, Lungu M and Craescu M: Predictive value of
immunological markers in systemic sclerosis. Exp Ther Med.
22(994)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Denton CP: Advances in pathogenesis and
treatment of systemic sclerosis. Clin Med (Lond). 16:55–60.
2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Matsumoto Y, Hayashi H, Tahara K, Yasuda
T, Tsubouchi S, Yamamoto Y, Mizuuchi T, Mori H and Sawada T:
Intravenous cyclophosphamide for gastric antral vascular ectasia
associated with systemic sclerosis refractory to endoscopic
treatment: A case report and review of the pertinent literature.
Intern Med. 58:135–139. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Lynch JP III and McCune WJ:
Immunosuppressive and cytotoxic pharmacotherapy for pulmonary
disorders. Am J Respir Crit Care Med. 155:395–420. 1997.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Konma J, Kotani T, Shoda T, Suzuka T,
Fujiki Y, Nagai K, Hata K, Yoshida S, Takeuchi T, Makino S and
Arawaka S: Efficacy and safety of combination therapy with
prednisolone and oral tacrolimus for progressive interstitial
pneumonia with systemic sclerosis: A retrospective study. Mod
Rheumatol. 28:1009–1015. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hughes M and Herrick AL: Digital ulcers in
systemic sclerosis. Rheumatology (Oxford). 56:14–25.
2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Khor CG, Chen XL, Lin TS, Lu CH and Hsieh
SC: Rituximab for refractory digital infarcts and ulcers in
systemic sclerosis. Clin Rheumatol. 33:1019–1020. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Beckett VL, Conn DL, Fuster V, Osmundson
PJ, Strong CG, Chao EY, Chesebro JH and O'Fallon WM: Trial of
platelet-inhibiting drug in scleroderma. Double-blind study with
dipyridamole and aspirin. Arthritis Rheum. 27:1137–1143.
1984.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Bobeică C, Tatu AL, Crăescu M and
Solovăstru L: Dynamics of digital ulcers in systemic sclerosis. Exp
Ther Med. 20:61–67. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Denton CP, Howell KS, Stratton RJ and
Black CM: Long-term low molecular weight heparin therapy for severe
Raynaud's phenomenon: A pilot study. Clin Exp Rheumatol.
18:499–502. 2000.PubMed/NCBI
|
|
15
|
Haustein UF: Systemic
sclerosis-scleroderma. Dermatol Online J. 8(3)2002.PubMed/NCBI
|
|
16
|
Goodfield MJ and Rowell NR: Treatment of
peripheral gangrene due to systemic sclerosis with intravenous
pentoxifylline. Clin Exp Dermatol. 14:161–162. 1989.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Berman B and Duncan MR: Pentoxifylline
inhibits the proliferation of human fibroblasts derived from
keloid, scleroderma and morphea skin and their production of
collagen, glycosaminoglycans and fibronectin. Br J Dermatol.
123:339–346. 1990.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Fiori G, Marzi T, Bartoli F, Bruni C,
Ciceroni C, Palomba M, Zolferino M, Corsi E, Galimberti M, Moggi
Pignone A, et al: The challenge of pet therapy in systemic
sclerosis: Evidence for an impact on pain, anxiety, neuroticism and
social interaction. Clin Exp Rheumatol. 36 (Suppl 113):135–141.
2018.PubMed/NCBI
|
|
19
|
Thakkar V, Nikpour M, Stevens WM and
Proudman SM: Prospects for improving outcomes in systemic
sclerosis-related pulmonary hypertension. Intern Med J. 45:248–254.
2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Channick RN, Simonneau G, Sitbon O,
Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M,
Bodin F and Rubin LJ: Effects of the dual endothelin-receptor
antagonist bosentan in patients with pulmonary hypertension: A
randomized placebo-controlled study. Lancet. 358:1119–1123.
2001.PubMed/NCBI
|
|
21
|
Rubin LJ, Badesch DB, Barst RJ, Galie N,
Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al:
Bosentan therapy for pulmonary arterial hypertension. N Engl J Med.
346:896–903. 2002.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rebegea L, Firescu D, Baciu G and Ciubara
A: Psycho-oncology support. BRAIN. 10:77–88. 2019.
|
|
23
|
Solovăstru LG, Stîncanu A, De Ascentii A,
Capparé G, Mattana P and Vâţă D: Randomized, controlled study of
innovative spray formulation containing ozonated oil and
α-bisabolol in the topical treatment of chronic venous leg ulcers.
Adv Skin Wound Care. 28:406–409. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
van den Hoogen FH, Boerbooms AM, Swaak AJ,
Rasker JJ, van Lier HJ and van de Putte LB: Comparison of
methotrexate with placebo in the treatment of systemic sclerosis: A
24-week randomized double-blind trial, followed by a 24-week
observational trial. Br J Rheumatol. 35:364–372. 1996.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Arakawa H, Yamasaki M, Kurihara Y, Yamada
H and Nakajima Y: Methotrexate induced pulmonary injury: Serial CT
findings. J Thorac Imaging. 18:231–236. 2003.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Steen VD and Medsger TA Jr: Case-control
study of corticosteroids and other drugs that either precipitate or
protect from the development of renal scleroderma crisis. Arthritis
Rheum. 41:1613–1619. 1998.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Steen VD, Costantino JP, Shapiro AP and
Medsger TA Jr: Outcome of renal crisis in systemic sclerosis:
Relation to availability of angiotensin converting enzyme (ACE)
inhibitors. Ann Intern Med. 113:352–357. 1990.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Steen VD and Medsger TA Jr: Long-term
outcomes of renal scleroderma crisis. Ann Intern Med. 133:600–603.
2000.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Bütikofer L, Varisco PA, Distler O,
Kowal-Bielecka O, Allanore Y, Riemekasten G, Villiger PM and Adler
S: EUSTAR collaborators. ACE inhibitors in SSc patients display a
risk factor for scleroderma renal crisis-a EUSTAR analysis.
Arthritis Res Ther. 22(59)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tyndal AJ, Bannert B, Vonk M, Airò P,
Cozzi F, Carreira PE, Bancel DF, Allanore Y, Müller-Ladner U,
Distler O, et al: Causes and risk factors of death in systemic
sclerosis: A study from the EULAR scleroderma trials and research
(EUSTAR) database. Ann Rheum Dis. 69:1809–1815. 2010.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gasbarrini A, Lauritano EC, Gabrielli M,
Scarpellini E, Lupascu A, Ojeti V and Gasbarrini G: Small
intestinal bacterial overgrowth: Diagnosis and treatment. Dig Dis.
25:237–240. 2007.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chong MS, Ng WK and Chan JK: Concise
review: Endothelial progenitor cells in regenerative medicine:
Applications and challenges. Stem Cells Transl Med. 5:530–538.
2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sukmawati D and Tanaka R: Introduction to
next generation of endothelial progenitor cell therapy: A promise
in vascular medicine. Am J Transl Res. 7:411–421. 2015.PubMed/NCBI
|
|
34
|
Tatu AL and Ionescu MA: Multiple
autoimmune syndrome type III-thyroiditis, vitiligo and alopecia
areata. Acta Endocrinol (Buchar). 13:124–125. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Nwabudike LC, Elisei AM, Buzia OD,
Miulescu M and Tatu AL: Statins. A review on structural
perspectives, adverse reactions and relations with son-melanoma
skin cancer. Rev Chim (Buchar). 69:2557–2562. 2018.
|
|
36
|
Mihăilă B, Dinică RM, Tatu AL and Buzia
OD: New insights in vitiligo treatments using bioactive compounds
from Piper nigrum. Exp Ther Med. 17:1039–1044. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zheng JN, Yang QR, Zhu GQ, Pan L, Xia JX
and Wang Q: Comparative efficacy and safety of immunosuppressive
therapies for systemic sclerosis related interstitial lung disease:
A Bayesian network analysis. Mod Rheumatol. 30:687–695.
2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Gonzalez-Nieto JA, Martin-Suares IJ and
Gil-Munoz FL: Eficacia del micofenolato asociado a metotrexato como
tratamiento de mantenimiento de la enfermedad pulmonary
intersticial asociada a la sclerosis sistémica. Arch Bronconeumol.
47(575)2011.
|
